Global cell and gene therapy market to reach $76b in 2030

It will be driven by significant advancements in gastrointestinal disorders treatments.

The global cell and gene therapy (CGT) market is forecasted to reach $76.03b in sales by 2030, at a compound annual growth rate of 44%, according to GlobalData.

It will be driven by significant advancements in gastrointestinal (GI) disorders treatments and innovations from both large and small pharma companies.

The report reveals that the CGT market for GI disorders, as a standalone therapy area, is expected to increase to $187mn in 2030 from $47m in 2023.

““However, challenges remain. As per the key opinion leaders interviewed by GlobalData, one major challenge is the lack of specific target genes across many, if not all GI disorders due to their polygenic nature,” Momna Ali, healthcare analyst at GlobalData, said.

Metabolic Dysfunction-Associated Steatohepatitis and Metabolic Dysfunction-Associated Steatotic liver disease account for the most CGTs in development, with 80 assets, of which 44 are antisense RNAi oligonucleotides (ASOs), followed by 15 cell therapies, 14 gene therapies, and 7 gene-modified cell therapies.